Pitocin After Birth (Third Stage of Labor) — Evidence Library

What it is

After baby is born, the uterus needs to contract firmly to close off the blood vessels where the placenta was attached. In many settings, a dose of synthetic oxytocin (Pitocin) is offered around the time of the placenta's delivery to support that process — this is sometimes called 'active management' of the third stage. In other settings, or by request, the third stage is managed more expectantly, watching how the uterus and bleeding behave before deciding whether to give a uterotonic. This is a separate conversation from Pitocin used to start or strengthen labor, and the personal context — history, risk factors, prior Pitocin exposure, plans for skin-to-skin and cord clamping — shapes what the trade-offs look like for any one person.

Evidence review links

Each link opens the full review on the publisher's site in a new tab.

Possible benefits

Research generally shows lower average blood loss and fewer postpartum hemorrhages when a uterotonic is given routinely after birth[WHO↗][Cochrane↗]
The reduction is largest for people with known risk factors for hemorrhage (for example, prolonged labor, induction or augmentation, multiples, prior hemorrhage, certain bleeding conditions)[ACOG↗][WHO↗]
It is the approach most major guidelines (WHO, ACOG, FIGO) currently recommend offering, while acknowledging the choice belongs to the birthing person[WHO↗][ACOG↗]

Possible risks

Common short-term effects can include nausea, headache, or stronger afterpains[Evidence Based Birth↗]
It does not eliminate the possibility of hemorrhage; monitoring after birth still matters either way[ACOG↗]
For low-risk births specifically, researchers and clinicians continue to discuss how much benefit routine use adds beyond careful watchful management[Evidence Based Birth↗][Cochrane↗]
Timing and route (IM vs. IV, before or after cord clamping) vary by setting and can affect experience and, in some studies, cord-blood volume to baby[Evidence Based Birth↗]

Alternatives

Expectant / physiologic management: no routine uterotonic, with close observation of the uterus, placenta, and bleeding[Evidence Based Birth↗][Cochrane↗]
'Selective' or 'wait-and-see' use: uterotonic given only if bleeding or uterine tone becomes concerning[WHO↗]
Immediate skin-to-skin and early breastfeeding, which support the body's own oxytocin release regardless of whether a dose is given[Evidence Based Birth↗]
Combining approaches — for example, delayed cord clamping first, then a uterotonic — where the care team is comfortable doing so[ACOG↗][Evidence Based Birth↗]

Current evidence

WHO, ACOG, and FIGO currently recommend that a prophylactic uterotonic (most often oxytocin/Pitocin) be offered as part of third-stage care to reduce postpartum hemorrhage, while framing it as a choice to discuss. Cochrane reviews of active vs. expectant management find lower average blood loss and fewer hemorrhages with active management, and also note effects like more nausea and afterpains. Evidence Based Birth's plain-language review walks through how those trade-offs shift based on individual risk, setting, and preferences. Reasonable clinicians and birthing people make different choices from the same evidence, and this page is meant to help you understand the conversation rather than argue for one path.

Where the evidence is clear · where people may choose differently

For most topics, guidelines from ACOG, WHO, and other major bodies broadly agree on the core safety points (when to act in an emergency, informed-consent standards, monitoring baselines). Where reasonable people — and even guidelines — differ tends to be around thresholds (when to start or stop something), preferences (comfort, environment, support), and values (how you weigh small risks against benefits). Use the questions below to explore those pieces with your care team.

Educational only. Your care team can help you weigh what applies to your specific situation.